Goldman Sachs
FRTX

Goldman Sachs’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Goldman Sachs’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,651
Closed -$74K – 5594
2020
Q2 		$74K Buy
+1,651
New +$87.9K ﹤0.01% 5030
2017
Q3 		– Sell
-41
Closed -$35K – 6920
2017
Q2 		$35K Buy
41
+4
+11% +$2.92K ﹤0.01% 6445
2017
Q1 		$26K Hold
37
– – ﹤0.01% 6455
2016
Q4 		$27K Sell
37
-3
-8% -$2.44K ﹤0.01% 6566
2016
Q3 		$38K Buy
40
+3
+8% +$3.79K ﹤0.01% 6565
2016
Q2 		$53K Hold
37
– – ﹤0.01% 6406
2016
Q1 		$46K Buy
37
+5
+16% +$5.77K ﹤0.01% 6468
2015
Q4 		$42K Hold
32
– – ﹤0.01% 6626
2015
Q3 		$47K Sell
32
-6
-16% -$11.6K ﹤0.01% 6816
2015
Q2 		$85K Buy
38
+2
+6% +$6.27K ﹤0.01% 6687
2015
Q1 		$109K Sell
36
-27
-43% -$86.4K ﹤0.01% 6399
2014
Q4 		$208K Sell
63
-50
-44% -$177K ﹤0.01% 6129
2014
Q3 		$400K Buy
113
+52
+85% +$202K ﹤0.01% 5480
2014
Q2 		$234K Buy
61
+38
+165% +$143K ﹤0.01% 6074
2014
Q1 		$93K Sell
23
-10
-30% -$44.6K ﹤0.01% 6415
2013
Q4 		$123K Buy
33
+26
+371% +$98.5K ﹤0.01% 6198
2013
Q3 		$29K Sell
7
-14
-67% -$105K ﹤0.01% 6385
2013
Q2 		$212K Buy
+21
New +$233K ﹤0.01% 5550

Other funds holding FRTX

PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSWM
Smith Salley Wealth Management Greensboro, North Carolina $2.3B AUM 38.65% 1-Year Est. Return

Goldman Sachs's FRTX Position: Q3 2020 in Review

Goldman Sachs sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2020, closing a stake of 1,651 shares — an estimated $74K sold.

Goldman Sachs first reported a position in FRTX in Q2 2013 and held it in 18 quarters. The position peaked at $400K in Q3 2014. 17 funds tracked by Wall St. Rank hold FRTX as of Q3 2020.

  • Goldman Sachs reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Goldman Sachs sold 1,651 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $74K.
  • Goldman Sachs first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
  • Goldman Sachs's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $400K in Q3 2014.
  • 17 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Goldman Sachs's 13F filing for Q3 2020, filed 13 Nov 2020.